These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26738170)

  • 1. A novel method for assessing the severity of levodopa-induced dyskinesia using wearable sensors.
    Lee SI; Daneault JF; Golabchi FN; Patel S; Paganoni S; Shih L; Bonato P
    Annu Int Conf IEEE Eng Med Biol Soc; 2015 Aug; 2015():8087-90. PubMed ID: 26738170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyskinesia Severity Estimation in Patients with Parkinson's Disease Using Wearable Sensors and A Deep LSTM Network.
    Hssayeni MD; Jimenez-Shahed J; Burack MA; Ghoraani B
    Annu Int Conf IEEE Eng Med Biol Soc; 2020 Jul; 2020():6001-6004. PubMed ID: 33019339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyskinesia estimation during activities of daily living using wearable motion sensors and deep recurrent networks.
    Hssayeni MD; Jimenez-Shahed J; Burack MA; Ghoraani B
    Sci Rep; 2021 Apr; 11(1):7865. PubMed ID: 33846387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Movement parameters that distinguish between voluntary movements and levodopa-induced dyskinesia in Parkinson's disease.
    Keijsers NL; Horstink MW; Gielen SC
    Hum Mov Sci; 2003 Feb; 22(1):67-89. PubMed ID: 12623181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Treatment-Response Index From Wearable Sensors for Quantifying Parkinson's Disease Motor States.
    Thomas I; Westin J; Alam M; Bergquist F; Nyholm D; Senek M; Memedi M
    IEEE J Biomed Health Inform; 2018 Sep; 22(5):1341-1349. PubMed ID: 29989996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Zesiewicz TA; Sullivan KL; Hauser RA
    Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing movement patterns associated with Huntington's chorea and Parkinson's dyskinesia.
    Mann RK; Edwards R; Zhou J; Fenney A; Jog M; Duval C
    Exp Brain Res; 2012 May; 218(4):639-54. PubMed ID: 22434341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.
    Li MH; Mestre TA; Fox SH; Taati B
    Parkinsonism Relat Disord; 2018 Aug; 53():42-45. PubMed ID: 29748112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease.
    Mann RK; Edwards R; Zhou J; Jog M; Duval C
    Clin Neurol Neurosurg; 2010 Jun; 112(5):392-9. PubMed ID: 20206438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review.
    Ebada MA; Alkanj S; Ebada M; Abdelkarim AH; Diab A; Aziz MAE; Soliman AM; Fayed N; Bahbah EI; Negida A
    CNS Neurol Disord Drug Targets; 2019; 18(4):317-325. PubMed ID: 30868968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task.
    Cerasa A; Pugliese P; Messina D; Morelli M; Gioia MC; Salsone M; Novellino F; Nicoletti G; Arabia G; Quattrone A
    Mov Disord; 2012 Mar; 27(3):364-71. PubMed ID: 22076870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
    Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated vision-based analysis of levodopa-induced dyskinesia with deep learning.
    Li MH; Mestre TA; Fox SH; Taati B
    Annu Int Conf IEEE Eng Med Biol Soc; 2017 Jul; 2017():3377-3380. PubMed ID: 29060621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.
    Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B
    Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous Assessment of Levodopa Response in Parkinson's Disease Using Wearable Motion Sensors.
    Pulliam CL; Heldman DA; Brokaw EB; Mera TO; Mari ZK; Burack MA
    IEEE Trans Biomed Eng; 2018 Jan; 65(1):159-164. PubMed ID: 28459677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect.
    Ramsperger R; Meckler S; Heger T; van Uem J; Hucker S; Braatz U; Graessner H; Berg D; Manoli Y; Serrano JA; Ferreira JJ; Hobert MA; Maetzler W;
    Parkinsonism Relat Disord; 2016 May; 26():41-6. PubMed ID: 26952699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
    Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
    J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.